Efficacy and safety of avanafil for treating erectile dysfunction: Results of a multicentre, randomized, double-blind, placebo-controlled trial

Chen Zhao, Sae Woong Kim, Dae Yul Yang, Je-Jong Kim, Nam Cheol Park, Sung Won Lee, Jae Seung Paick, Tai Young Ahn, Ki Hak Moon, Woo Sik Chung, Kweon Sik Min, Jun Kyu Suh, Jae Seog Hyun, Kwangsung Park, Jong Kwan Park

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). Preclinical and clinical phase I studies showed that avanafil had enhanced selectivity, faster onset of action and a favourable side-effect profile relative to currently available PDE5 inhibitors. As the result of phase III clinical trial for the efficacy and safety of avanafil treatment (100 and 200 mg), taken as needed over a period of 12 weeks, in Korean patients with ED, avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity. OBJECTIVE To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). PATIENTS AND METHODS The present study was a multicentre, randomized, double-blind, placebo-controlled, fix-dosed phase three clinical trial involving 200 patients with ED. The subjects were treated with placebo or avanafil (100 or 200 mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ). The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score. The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD ≥ 26), and response to the GAQ. RESULTS Compared with placebo, patients who took 100 or 200 mg of avanafil had significantly improved IIEF-EFD score. There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ. Flushing was the most common treatment-related adverse event. Most adverse events were transient and mild or moderate in severity. CONCLUSION Avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity.

Original languageEnglish
Pages (from-to)1801-1806
Number of pages6
JournalBJU International
Volume110
Issue number11
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Erectile Dysfunction
Placebos
Safety
Phosphodiesterase 5 Inhibitors
Therapeutics
Phase III Clinical Trials
avanafil
Clinical Trials
Surveys and Questionnaires

Keywords

  • avanafil
  • clinical study
  • erectile dysfunction (ED)
  • phosphodiesterase type 5 (PDE5) inhibitor

ASJC Scopus subject areas

  • Urology

Cite this

Efficacy and safety of avanafil for treating erectile dysfunction : Results of a multicentre, randomized, double-blind, placebo-controlled trial. / Zhao, Chen; Kim, Sae Woong; Yang, Dae Yul; Kim, Je-Jong; Park, Nam Cheol; Lee, Sung Won; Paick, Jae Seung; Ahn, Tai Young; Moon, Ki Hak; Chung, Woo Sik; Min, Kweon Sik; Suh, Jun Kyu; Hyun, Jae Seog; Park, Kwangsung; Park, Jong Kwan.

In: BJU International, Vol. 110, No. 11, 01.01.2012, p. 1801-1806.

Research output: Contribution to journalArticle

Zhao, C, Kim, SW, Yang, DY, Kim, J-J, Park, NC, Lee, SW, Paick, JS, Ahn, TY, Moon, KH, Chung, WS, Min, KS, Suh, JK, Hyun, JS, Park, K & Park, JK 2012, 'Efficacy and safety of avanafil for treating erectile dysfunction: Results of a multicentre, randomized, double-blind, placebo-controlled trial', BJU International, vol. 110, no. 11, pp. 1801-1806. https://doi.org/10.1111/j.1464-410X.2012.11095.x
Zhao, Chen ; Kim, Sae Woong ; Yang, Dae Yul ; Kim, Je-Jong ; Park, Nam Cheol ; Lee, Sung Won ; Paick, Jae Seung ; Ahn, Tai Young ; Moon, Ki Hak ; Chung, Woo Sik ; Min, Kweon Sik ; Suh, Jun Kyu ; Hyun, Jae Seog ; Park, Kwangsung ; Park, Jong Kwan. / Efficacy and safety of avanafil for treating erectile dysfunction : Results of a multicentre, randomized, double-blind, placebo-controlled trial. In: BJU International. 2012 ; Vol. 110, No. 11. pp. 1801-1806.
@article{4cac2d92e526470cad2d0685d26af956,
title = "Efficacy and safety of avanafil for treating erectile dysfunction: Results of a multicentre, randomized, double-blind, placebo-controlled trial",
abstract = "Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). Preclinical and clinical phase I studies showed that avanafil had enhanced selectivity, faster onset of action and a favourable side-effect profile relative to currently available PDE5 inhibitors. As the result of phase III clinical trial for the efficacy and safety of avanafil treatment (100 and 200 mg), taken as needed over a period of 12 weeks, in Korean patients with ED, avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity. OBJECTIVE To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). PATIENTS AND METHODS The present study was a multicentre, randomized, double-blind, placebo-controlled, fix-dosed phase three clinical trial involving 200 patients with ED. The subjects were treated with placebo or avanafil (100 or 200 mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ). The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score. The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD ≥ 26), and response to the GAQ. RESULTS Compared with placebo, patients who took 100 or 200 mg of avanafil had significantly improved IIEF-EFD score. There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ. Flushing was the most common treatment-related adverse event. Most adverse events were transient and mild or moderate in severity. CONCLUSION Avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity.",
keywords = "avanafil, clinical study, erectile dysfunction (ED), phosphodiesterase type 5 (PDE5) inhibitor",
author = "Chen Zhao and Kim, {Sae Woong} and Yang, {Dae Yul} and Je-Jong Kim and Park, {Nam Cheol} and Lee, {Sung Won} and Paick, {Jae Seung} and Ahn, {Tai Young} and Moon, {Ki Hak} and Chung, {Woo Sik} and Min, {Kweon Sik} and Suh, {Jun Kyu} and Hyun, {Jae Seog} and Kwangsung Park and Park, {Jong Kwan}",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1464-410X.2012.11095.x",
language = "English",
volume = "110",
pages = "1801--1806",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Efficacy and safety of avanafil for treating erectile dysfunction

T2 - Results of a multicentre, randomized, double-blind, placebo-controlled trial

AU - Zhao, Chen

AU - Kim, Sae Woong

AU - Yang, Dae Yul

AU - Kim, Je-Jong

AU - Park, Nam Cheol

AU - Lee, Sung Won

AU - Paick, Jae Seung

AU - Ahn, Tai Young

AU - Moon, Ki Hak

AU - Chung, Woo Sik

AU - Min, Kweon Sik

AU - Suh, Jun Kyu

AU - Hyun, Jae Seog

AU - Park, Kwangsung

AU - Park, Jong Kwan

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). Preclinical and clinical phase I studies showed that avanafil had enhanced selectivity, faster onset of action and a favourable side-effect profile relative to currently available PDE5 inhibitors. As the result of phase III clinical trial for the efficacy and safety of avanafil treatment (100 and 200 mg), taken as needed over a period of 12 weeks, in Korean patients with ED, avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity. OBJECTIVE To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). PATIENTS AND METHODS The present study was a multicentre, randomized, double-blind, placebo-controlled, fix-dosed phase three clinical trial involving 200 patients with ED. The subjects were treated with placebo or avanafil (100 or 200 mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ). The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score. The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD ≥ 26), and response to the GAQ. RESULTS Compared with placebo, patients who took 100 or 200 mg of avanafil had significantly improved IIEF-EFD score. There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ. Flushing was the most common treatment-related adverse event. Most adverse events were transient and mild or moderate in severity. CONCLUSION Avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity.

AB - Study Type - Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Avanafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor newly developed for treating erectile dysfunction (ED). Preclinical and clinical phase I studies showed that avanafil had enhanced selectivity, faster onset of action and a favourable side-effect profile relative to currently available PDE5 inhibitors. As the result of phase III clinical trial for the efficacy and safety of avanafil treatment (100 and 200 mg), taken as needed over a period of 12 weeks, in Korean patients with ED, avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity. OBJECTIVE To evaluate the efficacy and safety of avanafil, a new potent selective phosphodiesterase type 5 (PDE5) inhibitor, in patients with erectile dysfunction (ED). PATIENTS AND METHODS The present study was a multicentre, randomized, double-blind, placebo-controlled, fix-dosed phase three clinical trial involving 200 patients with ED. The subjects were treated with placebo or avanafil (100 or 200 mg) for 12 weeks and were asked to complete the International Index of Erectile Function (IIEF), the Sexual Encounter Profile (SEP) diary, and the Global Assessment Questionnaire (GAQ). The primary outcome variable was the change from baseline for IIEF erectile function domain (EFD) score. The secondary outcome variables were SEP Q2 and Q3, the shift to normal rate (EFD ≥ 26), and response to the GAQ. RESULTS Compared with placebo, patients who took 100 or 200 mg of avanafil had significantly improved IIEF-EFD score. There were similar results when comparing Q2 and Q3 in the SEP diary and the GAQ. Flushing was the most common treatment-related adverse event. Most adverse events were transient and mild or moderate in severity. CONCLUSION Avanafil is an effective and well-tolerated therapy for ED of broad-spectrum aetiology and severity.

KW - avanafil

KW - clinical study

KW - erectile dysfunction (ED)

KW - phosphodiesterase type 5 (PDE5) inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84870885982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870885982&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11095.x

DO - 10.1111/j.1464-410X.2012.11095.x

M3 - Article

C2 - 22448738

AN - SCOPUS:84870885982

VL - 110

SP - 1801

EP - 1806

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11

ER -